$1.81
1.63% today
NYSE, Apr 02, 10:10 pm CET
ISIN
US75062E1064
Symbol
RFL
Sector
Industry

Rafael Holdings Inc - Ordinary Shares - Class B Stock price

$1.81
-0.08 4.23% 1M
-0.17 8.59% 6M
+0.16 9.70% YTD
+0.09 5.23% 1Y
-0.98 35.13% 3Y
-10.15 84.87% 5Y
-3.09 63.06% 10Y
NYSE, Closing price Wed, Apr 02 2025
-0.03 1.63%
ISIN
US75062E1064
Symbol
RFL
Sector
Industry

Key metrics

Market capitalization $58.96m
Enterprise Value $16.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 22.83
P/S ratio (TTM) P/S ratio 83.04
P/B ratio (TTM) P/B ratio 0.66
Revenue growth (TTM) Revenue growth 156.73%
Revenue (TTM) Revenue $710.00k
EBIT (operating result TTM) EBIT $-14.58m
Free Cash Flow (TTM) Free Cash Flow $-8.64m
Cash position $48.32m
EPS (TTM) EPS $-2.11
Short interest 0.64%
Show more

Is Rafael Holdings Inc - Ordinary Shares - Class B a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Rafael Holdings Inc - Ordinary Shares - Class B Stock Analysis

Unlock Scores for Free

Financial data from Rafael Holdings Inc - Ordinary Shares - Class B

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jan '25
+/-
%
0.71 0.71
154% 154%
100%
- Direct Costs 0.58 0.58
544% 544%
82%
0.13 0.13
28% 28%
18%
- Selling and Administrative Expenses 9.02 9.02
9% 9%
1,270%
- Research and Development Expense 5.34 5.34
72% 72%
752%
-14 -14
27% 27%
-2,004%
- Depreciation and Amortization 0.35 0.35
289% 289%
49%
EBIT (Operating Income) EBIT -15 -15
29% 29%
-2,053%
Net Profit -50 -50
2,458% 2,458%
-7,108%

In millions USD.

Don't miss a Thing! We will send you all news about Rafael Holdings Inc - Ordinary Shares - Class B directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rafael Holdings Inc - Ordinary Shares - Class B Stock News

Neutral
GlobeNewsWire
7 days ago
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare...
Neutral
GlobeNewsWire
20 days ago
The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo's lead clinical program Trappsol ®  Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ende...
Neutral
Business Wire
about one month ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cyclo Therapeutics, Inc. (the “Company”) (NasdaqCM: CYTH) and Rafael Holdings, Inc. (NYSE: RFL). KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger ...
More Rafael Holdings Inc - Ordinary Shares - Class B News

Company Profile

Rafael Holdings, Inc. owns interest in commercial real estate assets and clinical stage pharmaceutical companies. It operates through the Real Estate and Pharmaceuticals segments. The Real Estate segment refers to the real estate holdings. The Pharmaceuticals segment is comprised of debt interests and warrants in Rafael Pharmaceuticals and a majority equity interest in LipoMedix Pharmaceuticals. The company is headquartered in Newark, NJ.

Head office United States
CEO William Conkling
Employees 31
Founded 2017
Website www.rafaelholdings.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today